Lancet Publishes Covaxin Phase 2 Trial Results, Finds It Safe

The interim results of Covaxin’s Phase 3 trials, announced last week, are yet to be peer reviewed.

On 8 March, The Lancet published the results of Phase 2 trials of India’s first homegrown COVID-19 vaccine, Covaxin, declaring it to be "safe, immunogenic with no serious side effects", reported NDTV.

The Lancet has also clarified that the efficacy of the vaccine cannot be determined until the results of Phase 3 are reviewed.